Alpha-lipoic acid    (DrugBank: Lipoic acid, alpha-Lipoic acid)

2 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
13Multiple sclerosis/Neuromyelitis optica1

2. Amyotrophic lateral sclerosis    [ 508 clinical trials,   530 drugs,   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways]
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 508 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005152-40-IT
(EUCTR)
19/04/200607/04/2006MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALSMULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, TRIAL ON ALPHA-LIPOIC ACID FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS ALALS - ALALS ALS
MedDRA version: 6.1;Level: PT;Classification code 10002026
Product Name: ALPHA-LIPOIC ACID
INN or Proposed INN: Tioctic acid
AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINONULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
84Italy

13. Multiple sclerosis/Neuromyelitis optica    [ 3,050 clinical trials,   2,147 drugs,   (DrugBank: 348 drugs),   244 drug target genes,   228 drug target pathways]
Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 3,050 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00010842
(ClinicalTrials.gov)
September 19992/2/2001Natural Antioxidants in the Treatment of Multiple SclerosisNatural Antioxidants in the Treatment of Multiple SclerosisMultiple SclerosisDrug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acidsNational Center for Complementary and Integrative Health (NCCIH)NULLCompletedN/AN/ABothPhase 1;Phase 2United States